Last reviewed · How we verify
BEBT-109 Capsule
At a glance
| Generic name | BEBT-109 Capsule |
|---|---|
| Also known as | KCBT-1083 |
| Sponsor | BeBetter Med Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer (PHASE2)
- Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEBT-109 Capsule CI brief — competitive landscape report
- BEBT-109 Capsule updates RSS · CI watch RSS
- BeBetter Med Inc portfolio CI